# Hydralazine

Drug · id `cardio:hydralazine` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Hydralazine hydrochloride

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

Hydralazine is a direct vasodilator, a medicine taken by mouth that the label says apparently lowers blood pressure by relaxing the muscle in blood vessel walls. The US label read, for generic hydralazine hydrochloride tablets, lists essential hypertension, alone or as an adjunct (an add-on to other treatment). The label says the precise mechanism of action is not fully understood.

## Technical summary

RxNorm ingredient 5470 (hydralazine hydrochloride is 82027); UNII FD171B778Y is the UNII of the hydrochloride salt that the label gives, so it is a broad match. MeSH descriptor D006830 is Hydralazine. RxClass lists the FDA established pharmacologic class Arteriolar Vasodilator, the class the direct vasodilators page records for minoxidil; the record is filed under that page on that evidence, and the page gained the alias Arteriolar vasodilator for it. The label read is the Chartwell RX, LLC generic tablet label, application ANDA086242, effective 2025-12-10 in openFDA, the label the class page already uses. The UNII and application number come from the openFDA record as read on 2026-11-09; the record read again on 2026-11-18 has the same effective date but no longer carries those fields. The plan row's label (set id 024ac6b8) was not read, and the combination products that contain hydralazine were not read. This page records the label indication and the mechanism sentences only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People with essential hypertension, as described in the US label of generic hydralazine hydrochloride tablets

Recipient: Recipient not specified; Population: Patients with essential hypertension, as the indications section of the label states. The label passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of hydralazine hydrochloride tablets (Chartwell RX, LLC, application ANDA086242; the version dated 2025-12-10 in openFDA) lists essential hypertension, alone or as an adjunct. It says the precise mechanism of action is not fully understood, and that hydralazine apparently lowers blood pressure by a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with essential hypertension, as the indications section of the label states. The label passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for a generic product; the brand label and the combination products that contain hydralazine were not read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-09T13:17:45Z. Source state: Current. Version fingerprint: 4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0.
     How it applies: Application number of the label read.
  2. Background: openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:45Z. Source state: Current. Version fingerprint: 4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0.
     How it applies: Effective date of the label text read.
  3. Supports: openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-11-09T13:17:45Z. Source state: Current. Version fingerprint: 4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0.
     How it applies: Label passage quoted in the research quote table (HYD-LB-04).
  4. Supports: openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1>
     Locator: results\[0\].clinical\_pharmacology\[0\]. Retrieved 2026-11-09T13:17:45Z. Source state: Current. Version fingerprint: 4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0.
     How it applies: Label passage quoted in the research quote table (HYD-LB-05, HYD-LB-06).

## Connected pages

- Hydralazine is an arteriolar vasodilator (FDA established pharmacologic class in RxClass), the class the direct vasodilators page records: Direct vasodilators (hydralazine, minoxidil) (`cardio:direct-vasodilators-hydralazine-minoxidil`)
- FDA label lists essential hypertension, alone or as an adjunct, as the indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-hydralazine-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: a720f56047a97697bf4062548a20b76ce78b6557d6c413051cbce1013ae25590
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
